15 / 366
ABSTRACTS
Abstracts
29th European Congress of Pathology
Oral Free Paper Sessions
OFP-01-001
The role of R21 expression in differential diagnosis of melanocytic
lesions
D. Turcan
*
, O. Pasaoglu
*
Eskisehir Osmangazi University, Dept. of Pathology, Turkey
Objective:
R21 is a mouse monoclonal antibody directed against amino
acids 203
–
216 of human soluble adenylyl cyclase protein. The aim of this
study is to evaluate the usefulness of R21 expression in the differential
diagnosis of melanocytic nevi (MN) and malignant melanomas (MM).
Method:
R21 immunostaining was performed in 50 cases of MM (24 nod-
ular melanomas, 9 superficial spreading melanomas, nine lentigo maligna
melanomas, seven acral lentiginous melanomas, 1 unclassified) and 50 cases
of MN (19 common melanocytic nevi, 19 dysplastic melanocytic nevi, 12
Spitz
’
s nevi) diagnosed in our department between 2010 and 2016. Two
different thresholds, 10 and 50 %, were used for positivity.
Results:
The difference between these two entities was statistically sig-
nificant for both cut-offs (
p
< 0.001). At the threshold of above 10 %R21-
stained cells, the sensitivity was 72 %, specificity was 92 %, positive
predictive value (PPV) was 90 % and negative predictive value (NPV)
was 76 %. At the threshold of above 50 % R21-stained cells, the sensi-
tivity was 60 %, specificity was 94%, PPV was 90% and NPVwas 70 %.
Conclusion:
Results of this study indicate R21 may have utility in the
differential diagnosis of MM and MN.
OFP-01-002
PD-1 expression and its relation with histologic and clinical variables
in mycosis fungoides
C. Vasquez
*
, C. Fumagalli, C. Pons, J. Muñoz, J. Szafranska, P. Garcia
Muret, S. Novelli, A. Mozos
*
Hospital de Sant Pau, Dept. of Pathology, Barcelona, Spain
Objective:
Micosis Fungoides (MF) has an indolent evolution, and most
cases have a prominent microenvironment. PD1 is expressed on activated T
cells, interacts with its ligands and plays a role in microenvironment modu-
lation. The aims of this study are to evaluate PD1 expression in MF cells, and
to identify histologic variables that might have an impact on clinical outcome.
Method:
66 patients with MF were reviewed (37 males; 29 females,
median follow-up:125 months (range 6
–
450 months). All cases were
stained with PD1 (clone NAT105) and its expression was evaluated.
Results:
MF cells express PD1 in a high proportion of cases (87.9 %).
Only atypia, age >60 yo and advanced stage had an negative impact on
overall survival (
p
< 0.05). Other histological variables, such as
epidermotropism, tumour microenviroment and CD7 expression did not
reach statistical significance. There was a weak correlation between
atypia and proportion of cells with PD1 expression, PD1 intensity, and
loss of CD7 expression (r < 0.5). The overall survival in the early stages
was 85 % vs.64 % in advanced stages (
p
< 0.05).
Conclusion:
In our series, we demonstrate a correlation between PD1 and
atypia, and between atypia and overall survival. However, most of our
cases expressed PD1, and therefore it might be a therapeutic target.
OFP-01-003
Up-regulation of FOXP1 in melanoma cells is a new unfavourable
prognosticator and a specific predictor of lymphatic dissemination in
cutaneous melanoma patients
P. Donizy
*
, J. Marczuk, K. Pagacz, W. Fendler, A. Halon, R. Matkowski
*
Wroclaw Medical University, Dept. of Pathomorphology, Poland
Objective:
To assess FOXP1 expression in tumour cells (TCs) and
tumour-associated immune cells (TAICs) of 96 cutaneous melanomas,
and analyze associations between FOXP1 expression and clinicopatho-
logical characteristics.
Method:
An immunohistochemical analysis was performed for FOXP1
in 96 formalin-fixed paraffin-embedded primary cutaneous melanoma
tissue specimens. The results were correlated with classical clinicopatho-
logical features and patient survival.
Results:
Enhanced expression of FOXP1 in TCs was strongly asso-
ciated with the presence of metastases in sentinel lymph nodes and
positive status of regional lymph nodes. 96 % (52/54) of patients
with low FOXP1 expression had no clinical or histopathological
features of lymphatic dissemination. On the other hand, increased
numbers of FOXP1-positive TAICs were observed in thinner and
non-ulcerated tumours. Moreover, up-regulation of FOXP1 in
TAICs was significantly associated with lack of regional lymph
node metastases. Kaplan-Meier analysis revealed that high expres-
sion of FOXP1 in TCs was significantly correlated with shorter
melanoma-associated overall survival and recurrence-free survival.
FOXP1 expression in TAICs was not associated with clinical out-
come. Multivariate analysis confirmed a significant impact of
FOXP1 expression on unfavorable prognosis in melanoma patients.
Conclusion:
Our results suggest that FOXP1 plays a key role in melano-
ma progression and is a potential target for molecular-based therapies.
OFP-01-004
Characterisation of the immunomodulatory effects of nivolumab and
i p i l i l uma b i n a d v a n c e d me l a n oma b y q u a n t i t a t i v e
immunohistochemistry
R. Edwards
*
, J. Black, T. Young, F. Aeffner, J. Major, E. Neely, L.
Cerkovnik, C. Mahrt, S. Kanaly, C. Horak, M. Montalto
*
Bristol-Myers Squibb, Translational Medicine, Princeton, USA
Objective:
Understanding the mechanism of PD-1 checkpoint blockade
will facilitate development of predictive biomarkers. We examined sev-
eral immune markers from patients with advanced melanoma who did
(IPI-T) or did not (IPI-N) receive ipilimumab prior to treatment with
nivolumab (Checkmate CA209-038).
Sunday, 3 September 2017, 08:30
–
12:00, G109
OFP-01 Joint Session: Dermatopathology / Head and Neck
Pathology
DOI 10.1007/s00428-017-2205-0
Virchows Arch
(
2017
)
471
(
Suppl 1
):
S1
–
S352